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The study was conducted primarily at the Department of Microbiology and Infection Control at 
the University Hospital of North Norway, Tromso, Norway. Patient samples were collected at 
Olafiaklinikken in Oslo, Norway for paper II and paper III. For paper IV, patient samples were 
collected at different laboratories in Norway. Some analyses were performed at the Swedish 
Reference Laboratory for Pathogenic Neisseria, Örebro, Sweden for paper IV as well as 
discrepancy analysis for paper II. 
The study was initiated to ensure appropriate diagnostics of N. gonorrhoeae in Northern 
Norway where general practitioners commonly treat patients for sexually transmitted infections 
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5 Introduction 
Sexually transmitted infections (STIs) are a global burden (1-3), with increasing number of new 
infections. Gonorrhoeae is the second most prevalent bacterial STI with a global estimated 
incidence of 88 million people annually (2005) (1,4,5). Effective condom use, diagnosis and 
timely adequate treatment of patients and their sexual contacts are the best available means to 
prevent spread of the infection in the absence of a vaccine.  
Unfortunately effective treatment is getting increasingly problematic due to rapidly developing 
antimicrobial resistance, and gonorrhoea may soon become untreatable in certain circumstances 
(6-8). The gold standard for diagnosing gonococcal infections has for many decades been 
culture, which however has limited sensitivity, in particular, in samples from rectum and 
pharynx. These extra-genital sites are also more problematic to treat, may commonly be 
asymptomatic, and act as reservoir for infection even in apparently successfully treated patients 
(9-12). Extra-genital samples can on the other hand be diagnosed using nucleic acid 
amplification test (NAAT) with improved sensitivity, but historically with poor specificity due 
to closely related commensal Neisseria species or Neisseria meningitidis.   
Historical background 
Ancient Chinese, Egyptian, Greek and Roman literature as well as the Bible, all describe 
symptoms related to gonorrhoea (13), and the term gonorrhoea stems from ancient Greek and 
was first used by Galen in 130 A.D, meaning flow of seed. Albert Neisser was the first to 
identify the aetiological agent of gonorrhoeae in 1879 in microscopy of stained smears from 
vaginal, urethral and conjunctival exudates (14) and termed it Micrococcus gonorrhoeae.  
Many other terms have historically been used for Neisseria gonorrhoeae; Gonococcus neisseri, 
Diplococcus gonorrhoeae, Micrococcus gonococcus, Micrococcus gonorrhoeae, 
Merismopedia gonorrhoeae, Micrococcus der gonorrhoe, Gonococcus neisseri (Lindau, 1898), 
Diplococcus gonorrhoeae (15,16) and Micrococcus gonococcus (Schroeter, 1886). 
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Prior to introduction of effective antimicrobial treatment of N. gonorrhoeae, urethral irrigation, 
abstinence from alcohol & sexual activity, rest and systemic treatment with various balsams 
were common treatment regimens (17). During World War One (WW1), prophylactic packets 
were handed out to soldiers, containing condoms, calomel ointment and Argyrol (18).   
Leistikow and Loeffler (Leistikow, 1882) successfully cultured N. gonorrhoeae and with the 
introduction of Gram staining (Gram, 1884), and carbohydrate oxidation test (Elser and 
Huntoon, 1909), diagnosis of gonorrhoea improved significantly. The discovery of 
sulphonamides for treatment of gonorrhoea (17), and later the discovery of penicillin (19,20) 
gave hope of eradicating gonorrhoea. As it turned out, N. gonorrhoeae has a remarkable ability 
to adapt to and survive any antimicrobial treatment, and continues as a major STI and public 
health concern worldwide. New phenotypic and genotypic knowledge about N. gonorrhoeae 
has elucidated the bacterium’s effective ability to evade the host immune system and 
environmental threats like antimicrobials. Gonorrhoea is here to stay. 
The bacterium 
The Neisseriaceae family are beta-proteobacteria which consists of Gram-negative aerobic 
bacteria from thirty genera including Neisseria, Eikenella, and Kingella (22). N. gonorrhoeae 
and N. meningitidis are the human pathogenic members of the Neisseria genus, which further 
includes several human and animal commensals. Commensal Neisseria and N. meningitidis are 
frequently part of the normal flora of especially the human oro- and nasopharynx (see table 1 
for a list of Neisseria species). All Neisseria species are non-motile, (despite some twitching 
motility, using their pili), aerobic, capnophilic, non-sporulating and inhabit the mucous 
membrane surface of warm blooded hosts (23). The bacteria are coccoidally shaped with 
exception of N. elongate and approximately 0.6 to 1.0 µm in diameter. They are usually seen in 
pairs with adjacent flattened sides, which gives them a characteristic kidney appearance in 
microscopy. N. gonorrhoeae is frequently found intracellular in polymorphonuclear leukocytes 
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(neutrophil granulocytes) of the gonorrhoea pustular exudate. It possesses a typical Gram-
negative outer membrane composed of proteins, phospholipids, and lipopolysaccharide (LPS). 
However, the neisserial LPS, with its highly branched basal oligosaccharide structure and the 
absence of repeating O-antigen subunits, differs from enteric bacteria. Because of these 
differences, neisserial LPS is referred to as lipooligosaccharide (LOS). N. gonorrhoeae is a 
fragile organism, susceptible to temperature changes, desiccation, UV-light, and many other 
environmental conditions (24). This contributes to the reduced sensitivity of culture diagnostics 
in comparison to NAATs as the sampling conditions and transport conditions (temperature and 
time) substantially affect the viability of gonococci. 
Despite being genetically similar, with 80-90% sequence homology in the genomic 
deoxyribonucleic acid (DNA), major cellular and molecular differences exist between the two 
pathogenic neisserial species. Both pathogens can colonize a variety of body sites and produce 
different symptoms. However, while N. meningitidis infections predominantly cause meningitis 
or septicaemia with a high mortality and low prevalence, N. gonorrhoeae typically causes 
urethritis and cervicitis with a high prevalence, but low mortality. N. meningitidis possesses a 
polysaccharide capsule which is not expressed by N. gonorrhoeae (25), and N. gonorrhoeae 
has up to 12 opacity (Opa) proteins, whereas N. meningitidis has three to four Opa proteins (26-
29). N. meningitidis expresses two different porins (30-33); PorA and PorB, while N. 
gonorrhoeae only expresses PorB. The porA gene was long thought to be exclusive to N. 
meningitidis and forms the basis for genosubtyping of N. meningitidis (34). However, the gene 
was identified in N. gonorrhoeae (31,35), but a frame shift mutation in the coding region of the 
gene abolishes its expression (31,35). Nevertheless, this gonococcal porA pseudogene is 
enough different from the meningococcal porA gene for using it as specific target in genetic 
diagnostics of N. gonorrhoeae. The PorA protein is accordingly not essential for colonising the 
urogenital tract, and may even be disadvantageous. Hence the loss of expression of porA has 
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been suggested to reflect a step in the divergence into the two separate species of pathogenic 
Neisseria (31).  
The Neisseria species are very promiscuous and readily exchanges DNA with its surroundings. 
They harbour DNA uptake sequences (DUS), which are required for efficient natural genetic 
transformation (36), surrounding and within coding regions of their genes. DUS are typically 9 
– 10mer sequences, and 1900 are scattered throughout the Neisseria genome (36-39). The 
highest density of DUS is found within and in close proximity to genes involved in DNA 
repair, recombination, restriction modification and replication. N. gonorrhoeae are naturally 
competent in all phases of the growth cycle resulting in high frequency of horizontal transfer of 
genetic material between N. gonorrhoeae strains, and other Neisseria species (40-45).  
Mutations and homologous recombination’s also contribute to the genetic heterogeneity of N. 
gonorrhoeae (29,46-53). Most recombination will be conservative in its nature, and thus it is 
primarily a mechanism for genome repair and conservation. However recombination can 
occasionally give rise to diversity, some of which are beneficial to the bacterium.  
A high degree of recombination between chromosomal genetic loci causes antigenic variability, 
a key feature of panmictic or non-clonal pathogens (54-56). The resulting high level of 
genotypic variability (incorporation of new genetic material acquired, in particular, by 
transformation) and phenotypic variability (differential expression of existing parts of the 
genome) is important for evasion or adaptation to the immune response of the host. This also 
aids the development of, or spread of antibiotic resistance mechanisms.  
 Combined with N. gonorrhoeae’s ability to produce mildly symptomatic or asymptomatic 
infection, the high level of genotypic and phenotypic variability also aids the bacteria in 
persistence without severely damaging the host. 
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Table 1. Different Neisseria species, their natural hosts and known pathogenic status.  








N. weaver N. canis (Cat) 
N. lactamica N. denitrificans (Guinea pig) 
N. polysaccharea N. weaverii (Dog) 
N. cinerea N. iguanae (Iguanid lizards) 
N. flavescens N. ovis (Cattle) 
N. sicca N. caviae (Guinea pig) 
N. mucosa N. cuniculi  (Rabbit) 
N. baciliformis N. macacae (Rhesus monkey) 
N. subflava 
 Biovar subflava 
 Biovar flava  





 N. elongata 
 N. glycolytica 
 N. nitroreducens 








 N. gonorrhoeae 
 Subspecies  
 N. kochii 
 
N. meningitidis  
 
Clinical manifestation – symptoms 
For adults, N. gonorrhoeae infections are primarily contracted through sexual contact. The 
main infection-sites are urethral mucous membranes in men and the endocervix and urethra in 
women, but the oropharynx, conjunctiva, and rectum can also be infected. Transmission to 
neonates during birth can cause conjunctivitis (58).  
The incubation period is typically 1-7 days, even though it may vary. N. gonorrhoeae 
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infections have a variety of clinical presentations, all commonly also caused by other 
organisms. The infection gonorrhoea is, if symptomatic, usually attributed as a specific type of 
urethritis/cervicitis resulting in copious discharge of pus, more apparent in men than women. 
The gonococcal infection may however infect also other tissues such as mucosa in anorectal 
tract, oropharynx and conjunctiva. In men, untreated gonococcal infections may lead to urethral 
stricture and epididymitis, and ultimately infertility. In women, the infections are more often 
asymptomatic (50%) than for men (10-20%) and mostly result in symptoms such as dysuria, 
vaginal discharge and sometimes irregular bleeding. If left untreated the fallopian tubes and 
uterus can get infected, with further complications such as pelvic inflammatory disease (PID), 
ectopic pregnancy and infertility.  
For Human immunodeficiency virus (HIV) positives, a gonococcal infection may also lead to 
dramatically increased shedding and accordingly transmission of HIV (59), probably through 
an increase of the viral load in the semen (60) or cervico-vaginal fluids (60,61). An underlying 
N. gonorrhoeae infection or other symptomatic STI in the recipient may also cause elevated 
number of CD4 lymphocytes to be available for the HIV (62). 
Disseminated gonococcal infection (DGI) is a rare complication, were a systemic spread of the 
bacteria in the bloodstream may cause, e.g., dermatitis, arthritis, septicaemia, endocarditis, and 
meningitis. Only 0.5-3% of infected individuals develops DGI (63), and a combination of 
certain strains of N. gonorrhoeae and individual’s deficient in, for example, complement 
factors C7, C8 and C9 appear to be predisposing (64).  
 
Epidemiology 
Gonorrhoea remains a major STI worldwide, and in some countries it is as prevalent as 
Chlamydia trachomatis (1,4,5). In 1999, the global incidence of gonorrhoea was estimated at 
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62 million cases (65). In 2005 the estimates were 88 million cases (1). This increase may not all 
be indicative of a true rise in prevalence, because new optimised models and algorithms were 
used for the 2005 estimates. Accordingly, the 2005 estimates are believed to me more accurate 
than the 1999 estimates and clearly the incidence remains high in many less-resourced 
countries and also increasing in several developed, industrialised countries. In Norway, 
compared to previous years there was a substantial increase in the number of diagnosed N. 
gonorrhoeae cases in 2010 (n=411) due to the increased use of the NAAT presented in this 
thesis. This increase was predominantly due to the diagnosis of more than twice the number of 
pharyngeal and rectal gonorrhoea among men who have sex with men (MSM) patients 




Figure 1. Incidence of N. gonorrhoeae in Norway from 1922 to 2010 (number of new infections per 100 000 
population). Figures for 2011, are not ready when this thesis is submitted, by September 237 gonorrhoeae 





















Table 2. Epidemiology of N. gonorrhoeae diagnosed in Norway past 10 years. 
*
 In this table, other indicates that patients have not reported sexual preference. 
 
 
Gonococcal infections have been voluntarily recorded in Norway since 1922, and mandatory 
from 1975. Historically, reported clinical infections in Norway show three major peaks, i.e. one 
after WW1, one after WW2 and one corresponding to the sexual revolution that started in the 
1960ies. Only Sweden has longer recorded historical data than Norway and has reported similar 
data. The decline starting in the late 1970s in Norway is similar as the ones reported in the rest 
of the Scandinavian countries and the USA (66) and was probably due to the decreased size of 
the 18- to 24-year age group, changed sexual behaviour, improved diagnostic methods, 
adequate antibiotic treatment, effective contact tracing and fear of HIV and acquired 
immunodeficiency syndrome (AIDS) from the mid-1980s and onward (66,67). 









  Homo Hetero 
Mother 
Child 




2010 176 80 1 2 40 112       
2009 84 74 1 3 11 94       
2008 76 105 - - 22 97       
2007 66 68 - 1 11 89       
2006 58 78 - 6 10 78       
2005 66 98 - 5 14 90  1  3  1 
2004 96 74 - 3 13 74       
2003 55 80 - - 14 88   2 2   
2002 70 85 - - 12 66   1 6   
2001 54 192 - - 5 71   1 4   
2000 59 101 - - 17 78    2   
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However, it is important to keep in mind that the incidences are influenced by several factors 
like patterns of sexual behaviour, population demographics, economic and social conditions, 
and biases in the quality and quantity of the epidemiological data (67,68).  
Antimicrobial treatment & resistance 
N. gonorrhoeae is natively susceptible to many antimicrobials such as sulphonamides, 
penicillins, tetracyclines, aminoglycolides, macrolides, cephalosporins, and fluroquinolones. 
The choice of antimicrobial agent depends on site of infection and susceptibility of the bacteria. 
Pharyngeal infections are more difficult to treat than urogenital infections, due to different 
bioavailability of the drug (69). Currently extended-spectrum cephalosporins (ESCs) are the 
most widely recommended antimicrobials for treatment of gonorrhoea, either as a single oral 
dose or injected dose (intramuscularly most common). 
The promiscuous nature (ease of acquisition of resistance genes from other bacteria) and 
relatively high mutational rate in many genes encoding resistance determinants of the bacteria 
has resulted in a global increase in antimicrobial resistance (AMR) in N. gonorrhoeae. An 
effective AMR surveillance program is essential to optimize standard treatments. In numerous 
countries, including many with high disease rates, such surveillance is often lacking or of a 
poor quality (6). 
The introduction of sulphonamides as an effective treatment for gonorrhoea, soon led to 
resistance (70). However, penicillin was already in 1943 shown to be an effective drug for 
treatment of the widely spread sulphonamide-resistant N. gonorrhoeae strains (70). Penicillins 
became the drugs of choice, and a slow but steady rise of chromosomally-mediated decreased 
susceptibility led to increased doses during several decades (71). Penicillinase producing N. 
gonorrhoeae (PPNG; causing plasmid-mediated penicillin resistance) spread rapidly after they 
were first described in 1976 (72). The spread of PPNG resulted in increased use of tetracycline, 
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and later quinolones in many countries, and both tetracycline resistant and quinolone (e.g., 
ciprofloxacin and ofloxacin) resistant (QRNG) N. gonorrhoeae are now widespread and these 
drugs are therefore not recommended for first-line treatment (73,74).  
ESCs are now the most widely used drugs for treatment of gonorrhoea. However, during the 
recent decade there have been numerous reports of decreasing in vitro susceptibility worldwide 
and, most recently, also verified treatment failures with orally administered ESCs (cefixime) in 
Japan, Norway and United Kingdom (69,70,75-78); Futhermore, the reported cases of 
treatment failures with cefixime, are unfortunately caused by MDR-NG (multidrug resistant N. 
gonorrhoeae) with decreased susceptibility or resistance to, e.g., quinolones, azithromycin and 
penicillins as well. The susceptibility to ceftriaxone has the last decade also decreased 
worldwide and recently a case of clinical failure treating pharyngeal gonorrhoea was described 
in Europe (7). Worryingly, most recently the first gonococcal strain with high-level resistance 
to ceftriaxone (2-4 mg/L), related to a treatment failure, was found in Kyoto, Japan and 
characterised in detail (8). This calls for more frequent follow up and test of cure (TOC) 
worldwide, especially with lack of regular AMR surveillance in many countries that also needs 
to be substantially strengthen, increasing use of NAAT diagnostics and strictly receptive oral- 
and/or rectal sex in subpopulations of MSM.   
 So far there are no other reports on treatment failure for intravenously administered ESCs such 
as ceftriaxone. Consequently all cases of genital and pharyngeal gonorrhoea are now treated 
with high dose of intravenous ceftriaxone in Japan (75). The emergence of MDR-NG with ESC 
resistance in the Pacific Rim is thought to spread rapidly throughout the rest of the world in 
light of past experience with similar pattern of spread (6).  
The competent nature of N. gonorrhoeae and proximity to other closely related Neisseria 
species in the pharynx, treatment difficulties and predominantly asymptomatic infection in the 
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pharynx (69) and incorrect use of antimicrobial treatment, make the pharynx a possible hotspot 
for emergence of new types of resistance  as well as a reservoir for infection and its further 
spread (9). Commensal Neisseria commonly found in the pharynx, may also acquire resistance 





Table 3. Antimicrobial classes, mechanisms of action and genetic location of resistance for antimicrobials 





























































Neisseria gonorrhoeae sampling and diagnostics 
5.1.1 Sampling 
Samples for N. gonorrhoeae diagnostics may be taken by urethral swab, urine, cervical swab, 
vaginal swab, rectal swab, pharyngeal swab, conjunctival swab and in rare DGI cases from skin 
wounds, synovial fluid and blood. Different transport medium are traditionally used for culture 
diagnostics than for NAATs. Copan has however developed a new transport medium, the M40, 
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which is a liquid transport medium suitable for both culture and NAAT diagnostics. 
5.1.2 Diagnostic challenges 
The antigenic variability of the gonococcus is a survival mechanism in this one-host bacterium 
and has contributed to the difficulties to produce an effective vaccine. Maintaining effective 
diagnostics is therefore important in controlling the spread of N. gonorrhoeae. The ideal 
diagnostic test would be cheap, rapid, non-invasive, and have 100% sensitivity and specificity 
while also providing an AMR profile. Such a test does not exist despite decades of research and 
development efforts and a US$ 1 million reward offered by the Rockefeller Foundation in 
1995, which was later withdrawn. At present, culture diagnostics can be considered as the most 
complete test as it can provide an AMR profile in addition to detection. On the other hand, the 
sensitivity of culture diagnostics is largely dependent on sampling, transportation of samples 
and culture procedures. In addition sample types like pharyngeal swabs and rectal swabs 
frequently contain large quantity of other bacterial species, which outcompete the N. 
gonorrhoeae on the agar plate. In a study by Bachmann et al (79), culture diagnostics had a 
sensitivity of 50-65% compared to NAATs. 
Microscopy is a fast, cheap and reliable diagnostic method in skilled hands, but only for 
urethral swabs from symptomatic men. The low sensitivity in samples from asymptomatic men, 
cervix, rectum and pharynx makes microscopy time-consuming and expensive resulting in only 
presumptive positive results (80), because a negative result cannot exclude infection. Culture 
diagnostics has for long been the gold standard method for diagnosing N. gonorrhoeae. This is 
largely because it has exceedingly high specificity, and can provide a measure of AMR. It is 
performed on selective agar medium but still requires subsequent species-verifying test to 
confirm that it is N. gonorrhoeae. This method is time consuming and even under optimal 
conditions cultures has a relative low sensitivity compared to NAATs. This is due to 
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overgrowth of other bacteria (especially in pharyngeal and rectal samples) and low viability of 
the bacteria outside the host.  
NAATs are very sensitive and work well in any sample type used (i.e. urine, rectal swabs, 
pharyngeal swabs, urethral swabs, cervical swabs, and conjuctival). By using NAATs, AMR 
testing is not possible and hence assessing treatment outcome is hard to do, especially for 
patients not presenting symptoms upon initiation of treatment. The genetic relatedness between 
N. gonorrhoeae, N. meningitidis and the commensal Neisseria species, coupled with extensive 
exchange of genetic elements, make it difficult to find DNA sequences conserved and unique 
for N. gonorrhoeae. For this reason, specificity is a major concern, especially in extra-genital 
specimens. Many Neisseria species are genetically very similar and exchange DNA 
promiscuously, making molecular assays prone to reduced specificity (81). Both commercial 
and in-house NAAT assays have documented specificity problems (table 4).  
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Table 4. Select Nucleic acid amplification tests (NAATs), their target regions used for detection of 
N. gonorrhoeae and cross-reactions.  
Manufacturer Assay Name Amplification 
Technology 
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 Previously reported cross-reacting species are from reference Palmer, H. et al 2003(82) 
b
Reported cross reacting species are from reference Tabrizi, Z.N. et al 2011(81). 
c
Reported cross reacting species are from unpublished in-house results.  
d
Reported cross reacting species are from Tabrizi, Z. N. et al 2005 (83,84)   
e
 Reported cross reacting species are from Chui, L. et al 2008 (85) 
f
 Reported cross reacting species are from Goire, N. et al 2008 (86) 
 
5.1.3 Diagnostics 
Diagnosis of gonorrhoea based solely on clinical manifestations is very difficult and is only 
suggestive. This is due to the fact that the bacteria can cause both symptomatic and 
asymptomatic genital as well as extra genital tract infection with a broad spectrum of 
symptoms, many of which are similar to those of other STIs.  
5.1.3.1 Direct microscopy 
Gram staining followed by direct microscopy of sample smears from urethra, cervix, rectum 
and vagina from men and women can easily be prepared at the point of care (POC), searching 
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for Gram negative diplococci intracellular within polymorphonuclear leukocytes. Performed by 
a trained professional, this can be a good preliminary diagnosis of gonorrhoea. This method is a 
rapid diagnosis with sensitivity approaching culture diagnostics for urethral samples in 
symptomatic men (≥90%), which makes it possible to even provide a definitive diagnosis of 
gonorrhoea for these samples (73,74,87). However the method is relatively insensitive and does 
not provide a definitive diagnosis for specimens from asymptomatic men, women and extra-
genital sites from both sexes (≤50% sensitivity). For extra genital sites, the specificity is also 
suboptimal due to presenceof commensal Neisseria species and/or N. meningitidis. In any case, 
negative microscopy does not exclude infection for these samples. Both CDC (74) and the 
IUSTI/WHO (73) guidelines accept the use of microscopy for definitive diagnosis of 
gonorrhoea in urethral samples from symptomatic men. 
5.1.3.2 Culture diagnostics 
Culture diagnostics requires optimization of every step from specimen collection, 
transportation, inoculation and incubation to maintain high sensitivity. To maintain high 
specificity, the subsequent species verifying assays are important.  
It is recommended to use selective agar medium for N. gonorrhoeae. There are many known 
selective culture media; Martin-Lewis, Modified Thayer-Martin, GC-Lect, and New york City. 
These have a growth factors and antimicrobial agents in an agar or equivilant base. The 
antimicrobial agents (i.e. vancomycin, colistin, nystatin, and trimethoprim) prevent growth of 
Gram-positive bacteria, nongonococcal Gram-negative bacteria, fungi and swarming proteus 
species. For species verification of N. gonorrhoeae, microscopy, rapid oxidase production, 
carbohydrate utilization test, and rapid biochemical, substrate co-agglutination test, 
imunofluorescense assay or chromogenic enzme substrate tests are typically used. NAATs can 
also be used to verify positive cultures as N. gonorrhoeae. 
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5.1.3.3 Antimicrobial resistance testing 
Minimum inhibitory concentration (MIC) determination by agar dilution method is the 
reference method for antimicrobial susceptibilities determination in N. gonorrhoeae isolates. 
However this is a laborious method and a quality assured Etest® (Biomerieux, Marcy l'Etoile, 
France) is just as good, but easier to perform. The agar disc diffusion test however is not 
recommended.  
When clinical failures to respond to recommended therapies with specific antimicrobial agents, 
a resistant category is established with breakpoints for in-vitro determination of resistance after 
testing a variety of resistant isolates. In Europe a standardized set of breakpoints are set by the 
European committee on Antibmicrobial Susceptibility Testing (Eucast; www. Eucast.org)  
5.1.3.4 Nucleic acid amplification test 
All NAATs use specific primers sequences to guide enzymes to amplify specific sequences in 
the genome of the pathogen. The principle of amplification, enzymes and mode of detection of 
the amplified oligonucleotides vary between different methods. There is also a difference in 
what kind of nucleic acid target that is used. Both RNA (ribonucleic acid) and DNA 
(chromosomal or plasmid) are used as targets. RNAbased methods have a sensitivity advantage 
as one can target rRNA/mRNA, which can be present in 10-1000 copies. Plasmid targets have 
similar advantage due to possible multiple copies of plasmids. However, RNA is a more fragile 
nucleic acid and preserving buffers are needed for reliable results. Plasmids are not always 
evenly distributed during cell division, and may also be lost and readily exchanged. It is 
sometimes possible to find a multi-copy genomic DNA target gene, but such genes are often 
preserved between species and hence prone to false-positive test results.   
Polymerase chain reaction (PCR) utilizes a thermostable DNA polymerase enzyme to extend 
primers and thus amplify specific parts of DNA. Running an agarose gel electrophoresis and 
staining with ethidium bromide verifies the specific amplified products. This type of 
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conventional PCR is however not widely used as a diagnostic method for N. gonorrhoeae, but 
some laboratories use diagnostic conventional PCR method(s) for verifying culture positive 
samples, and some commercial such assays are available in resource poor settings as it requires 
less sophisticated equipment and are generally less expensive.  
Real-time PCR is the predominant NAAT used worldwide for microbiological diagnostics, in 
the format of in-house methods or commercially available kits. For N. gonorrhoeae, real-time 
PCR is used as in-house diagnostic assays (88-91), verification assays (92) and in commercial 
diagnostic assays such as, VERSANT CT/GC DNA 1.0 Assay (Siemens, Deerfield, IL, USA), 
COBAS TaqMan48 and 4800 (CT/NG) Test (Roche Molecular systems inc., San Diego, Calif) 
and RealTime CT/NG test (Abbott Laboratories, Abbot Park, Illinois, USA). Real-time PCR 
methods differ from conventional methods by detecting amplified products as an increase in 
emitted light, instead than after agarose gel electrophoresis. Specific regions of DNA are 
amplified using two primers, defining the outer borders of the region to be amplified, to mark 
starting points for the polymerase. A target specific probe complementary to a region between 
the primer sites is used for detection. The probe carries a quencher and a fluorophore to give a 
measure of increased DNA as increased light. A number of different probing systems are used, 
such as; TaqMan probes, Molecular beacons and Fret Probes. The most common probe used is 
the TaqMan probe or dual labelled hydrolytic probe. This probe binds the target quicker and 
harder than the primers as a design default and when bound to target is degraded by the 
polymerase as it elongates the primers. When degraded the fluorophore and quencher are 
separated and light emitted by the fluorophore will be measurable as an increase in light of 
specific wavelengths.  
Ligase chain reaction (LCR) (93,94) was used in the Abbot LCx assays (Abbot Laboratories, 
Abbot Park, Il, USA) for duplex detection of N. gonorrhoeae and C. trachomatis. The principle 
of LCR is based on ligation of two adjacent primers using a thermostable ligase enzyme, for 
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each of the strand in the two-stranded target DNA. Each of the ligated pair of primers will in a 
cycling reaction act as new templates for other primers. However, the Abbott LCx was 
previously recalled due to specificity as well as sensitivity problems (95). Developed at Gen-
Probe (Gen-Probe Inc., San Diego, Calif, USA), the transcription mediated amplification 
(TMA) technology is used in their APTIMA Combo 2 assay. The method uses two primers and 
two enzymes: RNA polymerase and reverse transcriptase. One of the primers contains a 
promoter sequence for RNA polymerase, which hybridizes to the target rRNA. Reverse 
transcriptase then makes a DNA copy of the target rRNA by extension from the 3'-end of the 
promoter primer. The RNase activity of the reverse transcriptase then degrades the RNA in the 
resulting RNA:DNA duplex. Next, the second primer binds to the DNA copy, and reverse 
transcriptase elongates the primer, making a new strand of DNA, resulting in a double-stranded 
DNA molecule. RNA polymerase recognizes the promoter sequence in the DNA template and 
initiates transcription. Each of the newly synthesized RNA amplicons re-enters the TMA 
process and serves as a template for a new round of replication.  
Strand displacement amplification (SDA) (96,97) and fluorescent energy transfer is used by 
Becton Dickinson in their BD ProbeTec ET Chlamydia trachomatis Amplified DNA Assay and 
/or the BD ProbeTec ET Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) 
Amplified DNA Assays.  
SDA is commonly explained as two steps; the generation step that creates the structure feeding 
into the second face – the exponential amplification step.  
The denatured target DNA is primed with two primers (S1 and S2), two bumpers (B1 and B1), 
and a detector probe. The primers have a target specific 3' end, and a non hybridizing 5' end 
with a BsoB1 recognition site between them.  
A polymerase and restriction enzyme extends primers and bumpers. When extending the 
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bumpers, the polymerase displaces the primer extension product, which then hybridizes to a 
complementary primer and bumper before another extension and displacement, and so on. The 
resulting products contain the annealing region for the detector probe flanked by BsoBI sites. 
Incorporation of alpha thio-dCTP in the complement to the restriction site ensures that BsoBI 
only nicks the extension products. The polymerase will extend from these nicks, resulting in 
exponential amplification. The amplified products are continuously detected using a detector 
probe with a target specific 3' end and a hairpin in the 5' end with a BsoBI recognition site in 
the loop. When the probe is annealed to correct target, the hairpin is linearized and a cleavable 
restriction site is made. When BsoBI cleaves at this site, the acceptor and fluorophore are 
distally separated, resulting in fluorescence. 
 
5.1.3.5 Other diagnostics 
Other diagnostic methods for diagnosing N. gonorrhoeae are direct fluorescent antibody (DFA) 
test, enzyme immunoassay (EIA), nucleic acid hybridization and syndromic diagnosis. Apart 
from nucleic acid hybridization, these methods have a very low sensitivity and commonly 
suboptimal specificity. 
The Digene Hybrid Capture II (Digene Corp., Beltsville MD, USA) (98) is the most common 
nucleic hybidization test for detecting N. gonorrhoeae and C. trachomatis and this method uses 
signal amplification to increase sensitivity. The sensitivity and specificity of Hybrid Capture II 
is lower than for optimized culture diagnostics (99-101), and do not provide AMR profiles. 
POC tests are often limited by their low sensitivity and should be used only for populations 
unlikely to return for follow-up. In these settings, rapid POC diagnostics, followed by 
immediate treatment of positive patients, with lower sensitivity than reference test are shown in 
several studies to lead to treatment of more patients where patients have to return for results 
 31 
and treatment (100,102). 
Where appropriate diagnostic facilities are not available, the World Health Organization 
(WHO) recommends the use of syndromic approach for diagnostic and treatment of bacterial 
STIs (especially urethritis and cervicitis) in both men and women. In regard to diagnosing 
gonorrhoea, syndromic management generally works well for urethritis in men. However, the 
low sensitivities and specificities for diagnosis of other gonococcal infections result in many 
false diagnoses (positives and negatives), and massive over-treatment as well as many STIs 
remain untreated (103). 
 
5.1.3.6 Test of cure 
Test of cure (TOC) is used in Norway to control the treatment outcome for both C. trachomatis 
and N. gonorrhoeae. As many gonococcal infections, especially in women are asymptomatic, a 
laboratory diagnostic test is required to assess treatment success. Since NAATs will detect 
nucleic acids also from non-viable pathogens and Chlamydial nucleic acid has been shown to 
reside for up to 2-3 weeks (104) after treatment, time for clearance of amplifiable nucleic acid 
had to be determined when introducing NAAT testing. We know from experience that far less 
than one week after effective treatment is enough to have a negative result using culture 
diagnostics for N. gonorrhoeae. Determination of appropriate time to do TOC with NAAT may 
depend on both the NAAT used for diagnostics, antibiotic used for treatment, and anatomical 
site of infection. 
Previous studies on TOC by Bachmann et al in 2002 (105), concluded that full clearance of 
gonococcal DNA after appropriate treatment of uncomplicated gonorrhoea was achieved within 
a week, but recommended TOC after 2 weeks for all type of gonococcal infections. Since both 
the diagnostic and treatment was different in their study, compared to Norwegian guidelines 
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and settings, we decided to investigate the appropriate time for TOC in the conditions relevant 
for Norway.  
The use of TOC for N. gonorrhoeae is debated and the literature and recommendations vary 
between no TOC for uncomplicated gonorrhoea and after 3-6 months for expedited partner 
therapy (4,73,74,106-108). CDC (4,74) recommends retest after 3-12 months rather than TOC 
for uncomplicated N. gonorrhoeae infection with the rationale that positives after treatment are 
likely to be re-infections when recommended treatment is provided. The IUSTI/WHO 
guidelines state that TOC is not routinely necessary for anogenital infection if a recommended 
treatment has been given, but an assessment to confirm compliance with treatment is 
recommended (73), looking at resolution of symptoms and partner notification. They do 
however recommend TOC in case of persistence of symptoms, re-exposure to infection, 
possibility of resistance to therapy, pharyngeal infections and if stipulated by national practice 
or guidelines (the latter being the case in Norway). Manavi et al. recommends TOC for 
pharyngeal infections (109) because of higher rate of treatment failure. Pharyngeal gonococcal 
infections can be exceedingly difficult to treat (10,109,110)  and are often asymptomatic 
resulting in potential reservoirs for infection and its further spread.  
The most support for not performing TOC is for uncomplicated urogenital gonococcal 
infections diagnosed with culture diagnostics and subsequent AMR testing performed 
(4,74,106-108). Culture diagnostics has a lower sensitivity for rectal samples due to overgrowth 
of other bacteria, and pharyngeal infections, in addition to lower diagnostic sensitivity, can be 
difficult to treat despite AMR testing indicating appropriate antibiotic, and hence TOC is more 
relevant for extra-genital samples. NAATs are rapidly replacing culture for detection of N. 
gonorrhoeae, and adequate evidence-based recommendations for appropriate time to perform 
TOC are lacking for non-culture diagnostics of gonorrhoea (105).  
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In Norway, the prevalence of N. gonorrhoeae is still low and the empiric treatment 
recommendation for gonococcal infection remains ciprofloxacin, making TOC crucial to 
perform to control the spread of gonorrhoea. 
TOC as part of gonorrhoea management may be controversial in different national, regional 
and international guidelines. However, it might be an important tool in the future to manage 
gonorrhoea, due to the increasing resistance to all recommended antibiotics for treatment, the 
importance of diagnosing and treating pharyngeal and rectal samples, and the increasing use of 
NAATs in diagnosing gonorrhoea. For asymptomatic patients, TOC is the only means of 
assessing treatment outcome.  
5.1.3.7 Molecular epidemiologic typing methods 
To understand the patterns of disease transmission, identify and target high-risk groups within 
communities, and to control outbreaks of antibiotic-resistant gonorrhea, we can use either 
partner notification, or molecular typing. Molecular typing methods assume that the bacterial 
isolate from individuals infected in a short transmission chain are genotypically 
indistinguishable (29,77). A carefully validated molecular typing method will recognize the 
relatedness of isolates by how similar they are to form the bases to construct a sexual network. 
Many different genes and methods have been explored for discriminatory power and ease of 
use (111-114).  
N. gonorrhoeae multiantigen sequence typing (NG-MAST) is so far the preferred method, 
providing means of comparison between laboratories via the Internet (115,116). NG-MAST 
sequences internal fragments of two highly polymorfphic antigen-encoding loci, the porB and 
tbpB genes (115,116).  
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6 Aims of the present thesis  
The main aims of the thesis were: 
I. To develop and clinically validate a robust, sensitive and specific real-time PCR for 
detection of N. gonorrhoeae to be used on a variety of sample types (paper I & II).  
II. To determine appropriate time for test of cure when diagnosing N. gonorrhoeae with 
NAAT (paper III). 
III. To characterize phenotypic and genotypic properties of N. gonorrhoeae isolates in 
Norway (paper IV). 
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7 Materials & Methods 
 Clinical N. gonorrhoeae isolates and reference strains 
7.1.1 Paper I 
To develop a porA real-time PCR, several international Neisseria reference strains (n=48) were 
collected from American Type Culture Collection (ATCC), Culture Collection University of 
Gothenburg (CCUG), National Collection of Type Cultures (NCTC), World Health 
Organization (WHO), Swedish Reference Laboratory for Pathogenic Neisseria, and Statens 
Serum Institut (SSI), Denmark. These reference strains included N. gonorrhoeae (n=34), N. 
meningitidis (n=4), Neisseria sicca (n=2), Neisseria subflava (n=1), Neisseria flavescens (n=2), 
Neisseria mucosa (n=2), Neisseria lactamica (n=2), and Neisseria cinerea (n=1). The N. 
gonorrhoeae reference strains originated from different geographic settings worldwide and 
were isolated during the last four decades.  
In addition to the international reference strains, we examined 168 clinical N. gonorrhoeae 
isolates, including 76 isolates cultured in Archangelsk, Russia in 2004, 14 isolates cultured at 
University Hospital of North Norway 2003-2004, 9 isolates from Norwegian Organization for 
Surveillance of Antibiotic Resistant Microorganisms (NORM), 13 isolates from SSI in 
Denmark, 5 confirmed N. gonorrhoeae isolates donated by Helen (82), and 51 genetically 
different Swedish N. gonorrhoeae isolates from 1998-2001 with known porA pseudogene 
sequence (35). In the paper we erroneously state that we examined 176 clinical samples, 
however 8 of these samples were not included in the following text. This means that 
everything, except the total number of samples examined, is correct.  
Furthermore, clinical isolates (n=54) of other Neisseria species were included. These 
comprised N. gonorrhoeae subspecies kochii (n=4), N. meningitidis (n=7), N. sicca (n=7), N. 
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subflava (n=11), N. flavescens (n=3), N. mucosa (n=5), N. lactamica (n=7), N. cinerea (n=7), 
Neisseria caviae (n=1), Neisseria animalis (n=1), and Neisseria polysaccharea (n=1).  
Specificity was tested using a panel of Gram-negative bacteria (n=18), Gram-positive bacteria  
(n=23), fungus (n=1) and viruses (n=4) as well as human DNA.  
7.1.2 Paper II 
To clinically validate the porA real-time PCR, a total of 284 samples from 242 consenting 
patients attending Olafiaklinikken in Oslo, Norway from January 2006 through May 2006 with 
suspected gonorrhoea where examined. Samples were collected using either a urethral flocked 
swab (Copan, Brescia, Italy) or an endocervical flocked brush (Copan, Brescia, Italy). The 
urethral swab was used for sampling in the urethra. The endocervical brush was used to take 
samples from the cervix, rectum and pharynx. 
7.1.3 Paper III 
To determine proper time for TOC, 234 men and 23 women were recruited at Olafiaklinikken 
in Oslo from June 2006 through January 2007. Samples for PCR were collected using either a 
urethral-flocked swab (Copan, Brescia, Italy) or an endocervical-flocked swab (Copan, Brescia, 
Italy). The urethral swab was used for sampling the urethra. The endocervical swab was used 
for sampling the cervix, rectum and pharynx. In total 669 clinical samples were collected from 
the 257 patients. Patients with positive samples who did not return for first TOC within 2 
weeks were excluded from the study.  
7.1.4 Paper IV 
To genetically and phenotypically characterize circulating Norwegian N. gonorrheae isolates, a 
total of 114 viable clinical isolates were collected from six university hospitals during 2009. 
These isolates comprised 42% of the total number of gonorrhoea cases in Norway in 2009, and 
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were initially cultured at the University Hospital of North Norway, Tromsø (n=3); St. Olavs 
Hospital, Trondheim University Hospital, Trondheim (n=6); Stavanger University Hospital, 
Stavanger (n=16); Haukeland University Hospital, Bergen (n=25); Oslo University Hospital, 
Ullevål Hospital, Oslo (n=60); and Akershus University Hospital, Oslo (n=4).  
 
DNA extraction  
7.1.5 Paper I 
Genomic DNA from the bacteria was isolated with a BioRobot M48 from Qiagen (Hilden, 
Germany) using the MagAttract DNA tissue kit with the Infectious Disease protocol and an 
elution volume of 100 l, according to the manufacturers specifications. All bacteria and the 
fungus were initially suspended in 200 l TE-buffer, pH 8 (Ambion, Austin TX, USA) to 
approximately 1.5 × 10
8
 Colony Forming Units (CFU)/ml before isolation of DNA. All viruses 
were suspended in a virus in-house transport medium made from Minimum Essential Medium, 
Hepes buffer and Gentamicin (Gibco, Carlsbad, Calif, USA). 
7.1.6 Paper II & III 
Seven hundred l of the UTM-RT sample was put in a Tecan Miniprep-75 (Tecan, Männedorf, 
Switzerland) modified by NorDiag AS (Oslo, Norway), to perform DNA preparation with the 
BUGS´n BEADS STI kit (Genpoint). The principle of the kit is to immobilise bacteria onto a 
paramagnetic bead and remove the sample material. Then the bacterial cells are lysed and the 
nucleic acid is precipitated back to the magnetic bead and washed. The purified nucleic acid is 
then eluted for downstream use. The Tecan Miniprep-75 was modified to perform this 
procedure automatically. To avoid human error, the Tecan also prepare the PCR reaction by 
adding mastermix and DNA eluate.  
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7.1.7 Paper IV 
Genomic DNA was isolated using the BUGS`n BEADS STI-fast kit (CE/IVD) (NorDiag ASA, 
Oslo, Norway) on the NorDiag Bullet according to manufacturer’s instructions. The principle 
of the kit is the same as for paper II and III.  
 
Real-time PCR 
Primers and probe against the N. gonorrhoeae porA pseudogene were designed for a TaqMan 
assay by using Primer Xpress 2.0 (Applied Biosystems, Foster city, Calif., USA) according to 
manufacturer’s guidelines. The forward and reverse primer sequences for porA pseudogene 
were 5´-CCG-GAA-CTG-GTT-TCA-TCT-GAT-T-3´ (22 bp) and 5´-GTT-TCA-GCG-GCA-
GCA-TTC-A-3´ (19 bp) respectively. The sequence for the TaqMan probe for the porA 
pseudogene was 5´-FAM-CGT-GAA-AGT-AGC-AGG-CGT-ATA-GGC-GGA-CTT-BHQ-1-
3´. The primer and probe sequences, and the amplicon (255 bp) were compared with porA 
pseudogene sequences from a previous study (35) as well as all the genetic sequences deposited 
in GenBank.  
For the N. gonorrhoeae specific PCR we used TaqMan Fast Universal PCR Master Mix (2×), 
No AmpErase UNG on a 7900 HT Fast Real-Time PCR System (Applied Biosystems Foster 
city, Calif., USA). The Fast-PCR was run with 20 seconds activation of the polymerase at 
95 C, followed by 50 cycles of 95 C for 1 second and 60 C for 20 seconds. We used 11.5 l 
template added to 13.5 l reaction mix for each PCR sample. We also tested the robustness of 
the method by varying the sample volume in the PCR between 9 and 15 l, while keeping the 
reaction mix constant at 13.5 µl. The primers amplify a 102 base pair (bp) fragment of the porA 
pseudogene. The porA primers and probe were optimized as recommended by Applied 
Biosystems and final concentrations of 900 nM primers and 200 nM probe were found to be 
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optimal. 
For inhibition control, an Internal Amplification Control (IAC) was constructed by using 
composite primers that have N. gonorrhoeae specific 5`-end and a pGEM-luc plasmid 
(Promega Madison, Wi., USA) specific 3`-end, which amplify a 181 bp fragment of the Beta-
lactamase coding region (position 2988 – 3169). The forward and reverse primer sequences for 
making the IAC were 5´-GTT-TCA-GCG-GCA-GCA-TTC-ATG-GTC-TGA-CAG-TTA-
CCA-ATG-CTT-AA-3´ and 5’-CCG-GAA-CTG-GTT-TCA-TCT-GAT-TGC-TGG-CTG-
GTT-TAT-TGC-TG-3’-3´ respectively. The internal control probe sequence was (24 bp): 5’-
Yakima Yellow-CCA-TAG-TTG-CCT-GAC-TCC-CCG-TCG-Darkquencer3’. The five l of a 
10
-4
 dilution of the pGEM-luc plasmid was used as a template in a total volume of 50 l 
reaction mix with no UNG. Fifty nM of each of the composite primers were used. First it was 
heated to 95 C for 10 minutes, then 40 cycles of 95 C for 15 seconds and 60 C for 1 minute 
followed.  
Sequencing 
7.1.8 16s rRNA sequencing (Paper II) 
In cases of discrepant results, the samples were sent to the National Reference Laboratory for 
Pathogenic Neisseria, Department of Laboratory Medicine, Clinical Microbiology, Örebro 
University Hospital, Örebro, Sweden, for discrepant analysis using sequencing of the 16S rRNA 
gene (primers used for PCR: 5´-TGA-TCC-ARC-CGC-ASS-TTC-3´, 5´-AGA-GTT-TGA-




7.1.9 porA sequencing (Paper II) 
The entire porA pseudogene was sequenced as previously described (35). The porA 
pseudogene, was amplified using the primers from Feavers (5´-CGA-AGC-CGA-CAT-CAA-
ACA-GGG-3´ and 5´-AAT-GAA-GGC-AAG-CCG-TCA-AAA-ACA-3´). The amplified porA 
pseudogene was sequenced using primers from Feavers (5´-AAT-GAA-GGC-AAG-CCG-
TCA-AAA-ACA-3´, 5´-AAA-CAG-GGC-AAA-ATC-TAT-GTC-3´, 5´-AAT-ACG-AGG-
GCG-GTA-AGT-TTT-T-3´, and 5´-ATG-CGA-AAA-AAA-CTT-ACC-GCC-CTC-3´) and 
Suker  (5´-AAC-GGA-TAC-GTC-TTG-CTC-3´, 5´-GAG-CAA-GAC-GTA-TCC-GTT-3´, 5´-
GGC-GAG-ATT-CAA-GCC-GCC-3´, and 5´-GGC-GGC-TTG-AAT-CTC-GCC -3´) 
(31,33,35). The reactions were performed in 96-well plates in a GeneAmp PCR system 2700 
(Applied Biosystems). The nucleotide sequences were determined using an ABI PRISM 3100 
Genetic Analyzer (Applied Biosystems) according to the manufacturer’s instructions. The 
sequence of each strand of each compiled sequence was determined (35). 
 
7.1.10 porB sequencing (Paper IV): 
The coding region of the porB gene was amplified using the PorBU (5´-CCG-GCC-TGC-TTA-
AAT-TTC-TTA-3´) and PorBL (5´-ATT-AGA-ATT-TGT-GGC-GCA-G-3´) primers described 
by Unemo et al (50). The 50 μl reaction mixture contained 1.0 U DNA polymerase, 2.5 mM 
MgCl2, 0.1 mM deoxynucleoside triphosphates, 0.5 μM concentration of each primer, and 1 μl 
of the genomic DNA template. The cycling parameters: an enzyme activation step at 94°C for 
10 min, followed by 30 sequential cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 90 s. At 
the end of the final cycle, an extension phase at 72°C for 4 min was included before storage at 
4°C.  
The same primers were then used for cycle sequencing of the porB amplicon on an ABI PRISM 
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3100 Genetic Analyzer (Applied Biosystems, Foster City, Calif., USA). The sequence of each 
strand of each compiled sequence was determined. 
7.1.11 Neisseria gonorrhoeae multiantigen sequence typing (NG-MAST) (Paper 
IV) 
The more variable internal segments of porB (490 bp) and tbpB gene (390 bp), where 
sequenced as described previously (115,117). The sequenced fragments are uploaded to the 
NG-MAST web site (www.ng-mast.net) assigned different allele numbers and sequence types 
(STs).  
       
 
Culture diagnostics (Paper II & III) 
The culture diagnostics was performed at Ullevål University Hospital as part of their routine 
diagnostic services by identification of characteristic colonies on chocolate agar medium 
supplemented with inhibitory antimicrobials, i.e. 5 µg/ml trimethoprim lactate, 100 IE/ml 
colistin, 0.5 µg/ml lincomycin and 1 µg/ml Amphotericin B. For thorough species 
confirmation, oxidase test, identification of Gram-negative diplococcic in microscopy, sugar 
oxidation tests, and Phadebact GC Monoclonal test (Bactus AB, Solna, Sweden) were used.  
Antimicrobial resistance testing (Paper III-IV) 
In paper II and III, the isolates where tested for their susceptibility to ampicillin, erythromycin, 
spectinomycin, ciprofloxacin, ceftriaxone, cefotaxime, and tetracycline using Etest® according 
to manufacturers instruction.  
In paper IV, the isolates where tested for susceptibility to penicillin G, erythromycin, 
spectinomycin, ciprofloxacin, ceftriaxone, azithromycin, tetracycline, cefixime, and gentamicin 
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using Etest® according to manufacturers instruction. -lactamace production was investigated 
with nitrocefin solution (Oxoid, Vasingsoke, Hants, England). 
Interpretative criteria from the European Committee on Antimicrobial Susceptibility testing 
(EUCAST, 
http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCA
ST_breakpoints_v1.3_pdf.pdf) were used for paper III and IV, whereas national breakpoints 
from Norwegian Working Group for Antibiotics (NWGA) was used for paper II by the 
investigating laboratory  
 
Direct microscopy (Paper II & III) 
All smears were methylene blue- or Gram-stained and examined for typical intracellular, i.e. 





8 General Results 
Paper I & II 
The developed PCR method amplified all of the different N. gonorrhoeae international 
reference strains (n = 34) and N. gonorrhoeae clinical isolates (n = 176) but none of the isolates 
of the 13 different non-gonococcal Neisseria species (n = 68) available for testing. A panel of 
Gram-negative bacteria (n = 18), Gram-positive bacteria (n = 23), fungus (n = 1), and viruses (n 
= 4) as well as human DNA, was also negative.  
The limit of detection was determined to be less than 7.5 genome equivalents/PCR reaction.  
 
Of the 360 clinical samples (from 242 patients) included in paper II 37 samples were positive 
by both culture diagnostic and PCR, however the PCR method identified 15 additional positive 
samples (from 14 symptomatic patients). All 15 culture-negative/PCR positive samples were 
confirmed positive by both 16S and porA pseudogene sequencing. The PCR method showed a 
sensitivity, specificity, positive predictive value, and negative predictive value of 100% in this 
study. The population investigated were preselected on the basis of being at high risk of having 
a gonococcal infection, or as contacts of N. gonorrhoeae positive patients. This pre-selection 
accounted for an N. gonorrhoeae prevalence of 17.4%. 
Paper III 
Thirty N. gonorrhoeae positive patients that were diagnosed by culture (n = 27) and/or NAAT 
(n = 30), in at least one clinical specimen, were included in the study. The gender distribution 
was 2 women (mean age: 24.5 years, range: 21 to 28 years) and 28 men (mean age: 37.4 years, 
range: 22 to 58 years), of which 50% (n=14) were MSM. Seven clinical specimens (divergent 
anatomical sites) from seven different patients were positive using NAAT, but negative with 
culture. Three of these patients (10% of all positive patients) did not have any positive culture 
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sample from other anatomical sites and, accordingly, would have been false negative if culture 
were the only diagnostic test used. 
Twenty-five patients were diagnosed with gonorrhoea at a single genital site, two patients had 
only extra-genital gonorrhoea (pharyngeal and rectal), and three patients displayed multiple 
infected sites. All patients diagnosed with genital gonorrhoea reported symptoms such as 
discharge and dysuria, while all the extra-genital infections were asymptomatic.  
Nineteen patients (63%) returned for TOC within day seven (day four to seven) after treatment, 
and 16 (84%) of these were negative using NAAT. Two of the remaining positive patients, 
which had their initial TOC taken on day four and day six, deposited a negative sample within 
day 14 (day 11 for both patients). The last patient did not return before day 19, but then had a 
negative TOC. There were eleven (37%) patients who did not return for their initial TOC 
before day eight to 14 after treatment, and they were all negative.     
AMR testing was performed on N. gonorrhoeae isolates for 25 culture positive patients. 
Seventeen (68%) of these 25 isolates were ciprofloxacin resistant; however, no isolate was 
resistant to ceftriaxone or spectinomycin.  
Paper IV 
The mean age was 25 years (median age: 23 years, range: 18-53 years) and 35 (median age: 33 
years, range: 19-60 years) for women (n=17; 15%) and men (n=97; 85%), respectively. 
Heterosexual infection was reported for 81 patients (64 men, 17 women), homosexual infection 
was reported for 31 men and two men did not disclose their sexual preference.  
Seven of the seventeen (41%) women were infected by their steady partner, whereas only 13 
(13%) men were infected by their steady partner. Commercial female sex workers were given 
as source of infection by 9 (9.3%) men.   
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The results of the AMR testing of all N. gonorrhoeae isolates (n=114) are summarized in Table 
7. In total 78% (n=89) of the isolates were resistant, and one isolate (0.9%) had intermediate 
susceptivility to ciprofloxacin, which is the recommended first-line antibiotic for treatment of 
gonorrhoea in Norway. Four (3.5%) isolates were intermediate susceptible/resistant to cefixime 
(0.19-0.38 mg/L), two isolates (1.8%) displaed intermediate susceptivility/resistance to 
ceftriacone (0.9 mg/L), and 12 (11%) isolates were resistant to azithromycin. β-lactamase 
production causing high-level resistance to penicillins, was found in 41 (36 %). A penA mosaic 
allele was found in 17 (15%) of the isolates, including all isolates with intermediate 
susceptible/resistant to cefixime (n=4).  
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 0 0 0 0 114 (100) 
Gentamicin
b
 MIC range: 1.5 to 8 mg/L 
a
Breakpoints for susceptible (S≤x mg/L) and resistant (R>y mg/L) according to the breakpoints stated by The  
European Committee on Antimicrobial Susceptibility Testing (EUCAST; www.eucast.org/Clinical breakpoints/ 
Clinical breakpoints - bacteria (v 1.3)). 
b
No breakpoints have yet been stated for gentamicin. 
 
Among the 31 MSMs, 24 (77%) had strains resistant to ciprofloxacin while 64 of the 81 
heterosexuals (79%) had ciprofloxacin- resistant strains. No significant difference was found (p 
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= 0.854). All the four isolates displaying intermediate susceptibility/resistance to cefixime were 
cultured from males (2 MSM) in the age of 39-46 years infected in Oslo (n=3) and France 
(n=1). These four (all NG-MAST ST1407) isolates all contained a penA mosaic allele, which is 
a predictive indicator of decreased susceptibility to ESCs, especially cefixime (117-119). 
Further 13 isolates contained a penA mosaic allele, and excluding the four isolates mentioned 
above, these had the highest MIC of cefixime (0.094-0.125 mg/L). Of the 17 isolates with the 
penA mosaic allele, 11 were determined as ST1407 (10 of these were isolated from MSM). All 
but two penA mosaic allele positive isolates were from gonorrhoea cases contracted in Norway, 
14 of them in Oslo. The two foreign infections were one MSM and one heterosexual, both 
infected in France (ST1407 and ST3168, respectively). 
The NG-MAST results in total showed 72 different STs, of which 37 have not been previously 
described. The most frequent STs were ST1407 (9.6% of isolates), ST292 (6.1%) and ST5030 
(5.3%), which has not been described previously. Sixty-two STs (54%) and eight STs (7.0%) 
were represented by one isolate and two isolates, respectively.  
In total, 38 (39%) of the men were infected abroad, and Thailand was the most frequent place 
for contracting N. gonorrhoeae. For women, 29% of the patients were infected abroad. 
Symptoms were the reason for seeking medical care for 92 (94.8%) of the men and 9 (52.9%) 
of the women. 
Of the domestically contracted isolates and the isolates contracted abroad, 55/68 (81%) and 
34/45 (76%) respectively were ciprofloxacin resistant. Seventy-one percent (5/7) of the women 
infected abroad had ciprofloxacin resistant isolates, and nine (90%) of the women infected 
domestically had ciprofloxacin resistant isolates. For men, 29 (27 heterosexual)/38 (76%) of 
those infected abroad and 46 (23 heterosexual)/58 (79%) of those infected domestically had 
ciprofloxacin resistant isolates. No significant difference was found (p = 0.729). 
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The two isolates displaying intermediate susceptibility/resistance to ceftriaxone were both from 
MSM infected domestically. Two of the four isolates showing intermediate 
susceptibility/resistance to cefixime were from domestically infected MSM, one from a 
domestically infected heterosexual man and one heterosexual man infected in another European 
country. Among the 12 azithromycin resistant strains two were from women (1 domestically 
infected), one was from a heterosexual male infected abroad and nine from men (five of these 




General background and summary 
The Department for Microbiology and Infection Control at the University Hospital of North 
Norway is one of two laboratories, which provides diagnostic services to the three most 
northern Norwegian counties with a total size of 112.960 km
2
, an area almost the size of 
England (130 000 km
2
), with a population of 465 000 (England has a population of almost 50 
million). This makes diagnosis of N, gonorrhoeae by culture difficult with great distances for 
transport of clinical samples from the consulting general practitioner to the laboratory. In 
addition, the incidence of gonorrhoea in Norway is low – 8.4/100 000 (2010). This background 
makes it especially important to improve the diagnostics by establishing a sensitive and 
specific, clinically validated diagnostic NAAT for diagnosing N. gonorrhoeae. 
The positive predictive value (PPV) of a test is a function of true positives (TP)/ (TP + false 
positives (FP)), making the specificity of the assay as well as the prevalence of infection 
determining factors for PPV. The disease prevalence influences the PPV by influencing the true 
positive and false positive rates as seen in Table 6.   
Table 6. Demonstration of the effect of prevalence on probability of true positive using different sensitivities 
and specificities. 
Sensitivity 96.4% 98.0% 




10% prevalence 84% 97% 
5% prevalence 73% 95% 




By using stringent inclusion criteria for who should be tested for N gonorrhoeae; such as 
symptoms, sexual contact with known positive, risk behaviour, or risk group we create a 
population of patients actually tested where the prevalence is much higher than in the general 
population. This will increase the PPV markedly in low prevalence populations.  
Culture diagnostics has for decades been the gold standard internationally, despite suboptimal 
sensitivity, and NAATs have traditionally been hampered with poor specificity. The latest 
generation commercial NAATs have a substantially higher specificity, even though false 
positives still occur (81). The great distances and long transport times in Northern Norway 
made us suspect that culture diagnostics resulted in unacceptable high number of false 
negatives and we decided to develop a real-time PCR (Paper I). The results were very good 
(Paper I) and we therefore chose to clinically validate the method with both genital and extra-
genital samples (Paper II). No diagnostic assay is complete without an evidence-base for when 
a TOC should be sampled, especially with the currently recommended empirical treatment in 
Norway (ciprofloxacin), and we investigated this in paper III. As the empirical treatment with 
ciprofloxacin is certainly suboptimal, we chose to genotypically and phenotypically 
characterize the circulating Norwegian N. gonorrhoeae strains in paper IV. This work 
substantially strengthened the evidence-base for changing the national treatment guidelines and 
demonstrated a widespread import of important international strains and antimicrobial 
resistance patterns.  
Development and clinical validation of a real-time PCR for diagnostics 
The real-time PCR developed for this study has so far proven to be 100% specific in all 
comparisons to culture and sequencing, as well as direct testing of known commensal Neisseria 
species, N. meningitidis and other closely related bacteria. The method is in use by several 
laboratories (domestically and abroad) with excellent performance characteristics. Combined 
with the practice of applying stringent inclusion criteria, the method described in paper I and II, 
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offers a highly sensitive and specific NAAT for diagnosing gonorrhoea. 
Appropriate, quality assured NAATs are the preferred method for screening for and diagnosing 
N. gonorrhoeae in Europe and USA because of the superior sensitivity and ease of use 
compared to culture diagnostics. Meanwhile it is necessary to monitor AMR trends in every 
region/nation to maintain effective treatment guidelines. The ability of N. gonorrhoeae to take 
up, accumulate and maintain exogenous DNA, including AMR determinants, and the genetic 
similarity to other Neisseria species, makes it difficult to design reliable NAATs (6,59,81). 
This is exemplified by the finding by Whiley, et al. (120), showing a clinical N. gonorrhoeae 
harbouring an N. meningitidis porA sequence. Increased sequencing capacity has improved 
design prospects as ever increasing Neisseria genomes become available in databases. A 
potentially fruitful design approach could be to align DUS-poor regions of all Neisseria species, 
looking for N. gonorrhoeae unique sequences. This opens up possibilities to make dual target 
NAATs for diagnosing N. gonorrhoeae. Such self-confirming assays would be in compliance 
with current and upcoming guidelines recommending confirmation of N. gonorrhoeae positives 
in screening or diagnostics using NAATs, and could make it possible to get NAAT tests 
approved for extra-genital samples. Such an assay would also affect the PPV positively, 
making it more feasible and reliable to screen low prevalent populations for N. gonorrhoeae. 
Sequentially testing with two different PCR targets will also improve PPV. 
The design of our real-time PCR proved to give a diagnostic sensitivity and specificity needed 
to reliably diagnose gonorrhoea in scarcely populated areas with low prevalence (Paper I and 
II).  
Pharyngeal and rectal gonococcal infections can be difficult to treat (10,109,110) and are often 
asymptomatic resulting in potential reservoirs for infection. The ability to diagnose rectal and 
pharyngeal samples with NAAT is therefore of great value. The pharynx is also regarded as an 
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important site for recombination as several commensal Neisseria species are typically found 
there. The low number of pharyngeal and rectal samples available in each of the studies 
conducted in the present thesis was insufficient to fully conclude that our PCR method is highly 
reliable for these samples. However the total number of cases examined in paper I-III, provides 
good evidence to recommend using the method for extra-genital samples also. The ongoing use 
of the method as supplemental diagnostics for culture at Olafiaklinikken and at the University 
Hospital North Norway also supports the high sensitivity and specificity for both urogenital and 
extra-genital specimens. 
Improved diagnostics of N. gonorrhoeae and STIs in general can help limit the spread of HIV 
as it has been shown in several studies that an underlying STI can increase HIV transmission 5-
10 times (121). Furthermore it is critical to make a correct diagnosis including all body site 
infected, and administer effective therapy. Adequate treatment is important to prevent 
emergence of AMR as we are running out of treatment options for gonococcal infections 
(7,8,122,123). For the same reason representative and timely AMR surveillance programs are 
important to ensure that the most effective drugs are recommended and used in each setting.  
Even though increased sensitivity is a major driving force for the increased use of NAAT for 
diagnosis of N. gonorrhoeae, the social stigma and potential catastrophic family implications of 
a false positive diagnosis, have made specificity a priority over sensitivity. In cases of child-
abuse, in many countries, culture diagnostics is the only approved diagnostic method.  
It appears that the porA pseudogene is exceedingly conserved over time, probably due to lack 
of selective pressure, as it is not an expressed gene. There has not been identified any known 
functions for the dormant gene, but one may speculate that a gene without any function would 
at some point be deleted from the gonococcal genome if the metabolic burden is noticeable. 
However, no isolate of N. gonorrhoeae lacking the porA pseudogene, have been described. The 
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DUS sequence – ATG CCG TCT GAA (also called DUS10) – was found in one copy 9 kb 
upstream and two copies 18 and 30 bp downstream of the porA pseudogene (3011 kb 
downstream from the reverse primer). The search was performed on one whole genome 
(NC_002946) and revealed 1522 DUS10 in the genome, an average of 1 DUS10/1415 bp.   
Future work will involve finding a second target with similar specificity as the porA 
pseudogene assay to make a self-confirmatory assay to meet present and future regulatory 
requirements and to be prepared for possible isolates with a deletion or alteration in the porA 
gene or the advent of commensal Neisseria species acquiring a porA gene or pseudogene. 
Furthermore fitness studies to determine metabolic cost of maintaining the dormant porA 
pseudogene and knockout studies to look for unknown functions of the pseudogene could shed 
new light on the likelihood of emergence of porA pseudogene-free gonococcal isolates. 
 
Empirical determination of appropriate time for TOC 
In paper III all, but one individual (who did not deposit the second TOC until day 19), were 
negative inNAAT within two weeks after treatment. In that respect, we managed to find an 
appropriate evidence-based time for TOC on patients diagnosed with our NAAT and treated 
with cefixime. The AMR test results for the patients with a culture positive N. gonorrhoeae 
isolate showed that 17/28 (68%) were ciprofloxacin resistant. This secondary result of the study 
further supports previous reports (88,89,124) that the level of ciprofloxacin resistance in 
Norwegian isolates is too high to support continuing use of ciprofloxacin as empiric treatment. 
In paper III we also debate the need for TOC in the Norwegian gonorrhoea management in 
context of the internationally supported abolishing of TOC. Our approach to make it feasible to 
get patients back for TOC was to use the same time intervals as was normally used for culture 
diagnostics – one week. This gives a lower time-resolution than was achieved by Bachmann et 
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al, who used fiscal incentives to have patients do self-sampling everyday in form of urine 
specimens. Experience from Paper II indicated that weekly testing for clearance was practical 
as we could expect longer clearing time than one week. The Bachmann, et al. Study (105) 
reported shorter clearance time, with a difference for urine in men (mean of 1.6 days), urine in 
women (mean of 1.7 days), and vaginal specimens (mean of 2.8 days).  
The sampling method, treatment regimen and diagnostic method used are factors which explain 
why our study concluded that 2 weeks is appropriate for TOC, while Bachmann, et al. (105) 
observed full clearance by day 6 for male urine and day 9 for female vaginal swabs. However 
we managed to find an appropriate time for TOC valid for all sample types with the current 
diagnostics and treatment in the Norwegian population (primarily citizens of the capital). There 
is some concern that any later TOC than two weeks might be re-infection rather than treatment 
failure and should therefore be treated as such by doing contact-tracing again. 
Empiric treatment recommendation for gonococcal infection is still ciprofloxacin in Norway 
(125). However, we did not follow Norwegian guidelines treating our study population. This is 
based on antimicrobial surveillance reports (NORM), previous findings (89) and international 
reports (126-130).  The high proportion of ciprofloxacin resistant gonococcal isolates found in 
this study, indicates that there is an urgent need to change Norwegian guideline for gonorrhoea 
treatment.  
The use of TOC seems reasonable in Norway, bearing in mind the Norwegian treatment 
guidelines and the high level of ciprofloxacin resistant isolates circulating in Norway. Despite 
this, Norway is still a low incidence country (124), further supporting the use of TOC (due to 
its ease). This study and a previous study (89) also showed that culture fails to detect several 
positive patients in comparison with NAATs, even under optimal sampling and transport 
conditions. The general practitioners (GPs) have a major role in diagnoses and treatment of STI 
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in Norway and several other countries. The discrepancies between culture and NAAT 
diagnostics might even be larger in routine diagnostic among GPs due to long transportation 
time to laboratory. Increasing use of NAATs and the increasing number of circulating multi-
resistant N. gonorrhoeae isolates might warrant a future revision of international guidelines for 
management and follow-up of gonorrhoea, including recommendations of substantially more 
frequent use of TOC.  
 
Molecular characterization of Norwegian gonococcal isolates 
In paper IV, we collected all viable N. gonorrhoeae strains from six university hospitals in 
Norway to characterize the phenotypic and genotypic properties of circulating strains. These 
data were then coupled with epidemiological data from Norwegian surveillance system for 
communicable diseases (MSIS). The AMR testing revealed exceptionally high resistance level 
to the recommended empiric treatment in Norway – ciprofloxacin (78%). The work done for 
paper III reported 68% resistance two years prior to collecting isolates for paper IV. This shows 
a very frightening reluctance to change treatment regimens in light of empirical evidence. The 
present study also showed that the level of ciprofloxacin resistance was higher among isolates 
from individuals infected domestically (59%) compared to abroad (40%). According to the 
WHO, the empirical first-line treatment should be changed when the resistance exceeds 5% in 
the general population (and mainly any resistance in a high-risk group of frequent transmitters). 
As this thesis is finalized, changes to the guidelines have been announced (personal 
communication). Furthermore, some isolates displayed intermediate susceptibility/resistance to 
cefixime and ceftriaxone which have also been used in Norway for treatment of patients 
attending Olafiaklinikken in Oslo.  
The high number of resistance to ciprofloxacin Norway fits well with the international situation 
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(6) There are also increasing number of reports on verified clinical failures with cefixime from 
Norway (76), England (77) and Japan (131).  Recently, the first N. gonorrhoeae strain with 
high-level clinical resistance to ceftriaxone was identified in Japan and subsequently 
characterised in detail (8).  
Forty-one (36%) of the isolates analyzed in paper IV were β-lactamase producing, and 17 
(15%) displayed penA mosaic alleles. NG-MAST analysis revealed a highly diverse population 
with 72 different N. gonorrhoeae multiantigen sequence types. Thirty-seven of the sequence 
types (51.4%) had previously not been described. ST1407 has been found in Italy(132), 
England(133), Whales(133), Japan(134), and Sweden (118).  The large number of new 
sequence types might be expected, as there has never been a similar molecular mapping of 
circulating Norwegian strains. A large import of gonorrhoea (39% of the isolates) also helps 
explain the heterogeneous population of N. gonorrhoeae. The most commonly found ST was 
ST1407 (n=11), containing a penA mosaic allele, a predictor of decreased susceptibility to 
ESCs, especially cefixime (117-119). This ST1407 clone, including its genetically highly 
related variants, has been shown to spread in many countries worldwide and account for a 
substantial proportion of the multidrug resistant gonococci (118,133,134). In the present study, 
the proportion of isolates containing a penA mosaic allele was higher among MSM (39%) than 
in heterosexuals (6.2%), which also caused the higher level of isolates with intermediate 
susceptibility/resistance to cefixime found among MSM, partly explained by the circulating 
ST1407. The susceptibility to these ESCs, the last remaining treatment options in many 





We managed to establish a sensitive diagnostic NAAT while maintaining high specificity for 
diagnosing N. gonorrhoeae in a low prevalence population. The method was clinically 
validated and has worked well (present thesis and use in routine diagnostics in several 
laboratories) on both genital and extra-genital samples. Appropriate evidence-based time for 
TOC was established.  
New official figures from Norway show an increase from 95 to 215 of infected MSM from 
2009 to 2010. There is no indication that this increase only constitutes an increase in incidence. 
Two major clinics in Oslo changed their sampling routines during this period to include more 
rectal and pharyngeal samples and supplement analysis using the PCR method described in 
paper I-III. This translates to an increase in positives on a national level from 269 in 2009 to 
412 in 2010. Hopefully this enables better diagnostics of asymptomatic men who 
predominantly practice receptive oral and/or rectal sex, and that this in turn reduces spread of 
the infection domestically. The import of gonorrhoea and domestic heterosexual spread 
continues to be a challenge, especially with reports of treatment failures using ECSs (7,8,76). 
Furthermore, this thesis helped provide strong evidences to force a change in the Norwegian 
guidelines for treatment of gonorrhoea.  
A large study on the sensitivity and specificity of the latest generation commercially available 
NAAT for gonorrhoea diagnostics (81), confirms, especially for extra-genital specimens, the 
need for supplementary testing of gonorrhoea positive samples diagnosed with NAATs. 
Additional work remains to include such a secondary target in our method, even though our 
porA pseudogene based method has yet to produce false positive results. NAATs detecting N. 
gonorrhoeae specific DNA is an important supplement to traditional culture methods, but 
should be used with caution to avoid reporting false positive results. Implementation of a 
secondary, confirmatory assay or a self-confirming assay with two targets, is needed to get 
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Science is a lot like sex. Sometimes 
something useful comes of it, but that’s not 
the reason we’re doing it. 
- Richard Feynman- 
